Solute carrier family 34 member 2 (SLC34A2) is a transmembrane protein, which belongs to SLC34 family. The protein encoded by SLC34A2 is a sodium-dependent phosphate transporter type IIb (NaPi-IIb). It is a pH-sensitive transporter, expressed in small intestine, liver and lung. NaPi-IIb expression is also observed in female genital tract, endometrium, cervix, fallopian tube and not in ovary. In human chromosome, the gene SLC34A2 is localized on 4p15.2.
Specificity
The antibody detects endogenous levels of total SLC34A2 protein.
Immunogen
Synthetic peptide corresponding to residues near the C terminal of human Solute carrier family 34 (sodium phosphate), member 2
Biochem/physiol Actions
Solute carrier family 34 member 2 (SLC34A2) cotransports inorganic phosphate ion and sodium ion into epithelial cells. SLC34A2 is associated with various malignancies like papillary thyroid and breast carcinoma and lung adenocarcinoma. Knockdown of SLC34A2 downregulates phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signalling pathway, in turn inhibiting tumour cell proliferation and metastasis of hepatocellular carcinoma. SLC34A2 promotes tumour proliferation of bladder cancer, through upregulation of proto-oncogene c-Myc. Fetal and early embryonic development of lung requires high expression of SLC33A2 and is downregulated in NSCLC (non-small cell lung carcinoma). High expression of NaPi-IIb is observed in epithelial ovarian cancer. Overexpression of SLC34A2 promotes colorectal cancer progression. Mutations in SLC34A2 is related to pulmonary alveolar microlithiasis.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in pH7.3 PBS, 0.05% NaN3, 50% Glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
MicroRNA-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/beta-catenin pathway
Zhang X, et al.
Oncotarget, 7(12), 14569-14585 (2016)
Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas
Yin BWT, et al.
Cancer immunology research, 8(1), 3-3 (2008)
Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity
Ye W, et al.
Cell Death & Disease, 8(2), e2581-e2581 (2017)
Knockdown of SLC34A2 inhibits hepatocellular carcinoma cell proliferation and invasion
Li Y, et al.
Oncology Research, 24(6), 511-519 (2016)
A novel SLC34A2 mutation in a patient with pulmonary alveolar microlithiasis
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.